<SEC-DOCUMENT>0001193125-25-136654.txt : 20250606
<SEC-HEADER>0001193125-25-136654.hdr.sgml : 20250606
<ACCEPTANCE-DATETIME>20250606113515
ACCESSION NUMBER:		0001193125-25-136654
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20250606
FILED AS OF DATE:		20250606
DATE AS OF CHANGE:		20250606

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		251029490

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d81295d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:18%">&nbsp;</DIV></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT STYLE="white-space:nowrap">6-K</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:18%">&nbsp;</DIV></center>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">For the month of June 2025 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Commission File Number: <FONT STYLE="white-space:nowrap">001-31368</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SANOFI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Translation of
registrant&#146;s name into English) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">46, avenue de la Grande Arm&eacute;e, 75017 Paris, FRANCE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Address of principal executive offices) </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT>
<FONT STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">In June 2025, Sanofi published the press releases attached hereto as Exhibits 99.1, 99.2 and 99.3 which are
incorporated herein by reference. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP><U>Exhibit&nbsp;No.</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><U>Description</U>&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&emsp;&ensp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d81295dex991.htm">Press Release dated June&nbsp;3, 2025: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d81295dex992.htm">Press Release dated June&nbsp;3, 2025: ASCO: new Sarclisa data support subcutaneous administration with <FONT STYLE="white-space:nowrap">on-body</FONT> injector </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d81295dex993.htm">Press Release dated June&nbsp;5, 2025: Sanofi Launches 2025 Global Employee Stock Purchase Plan </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:9pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Dated: June&nbsp;6, 2025</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">SANOFI</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">/s/ <U>Alexandra Roger&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Alexandra Roger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: Head of Legal Corporate&nbsp;&amp; Finance</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d81295dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:14pt"><B>Press Release</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g81295g04g01.jpg" ALT="LOGO" STYLE="width:1.52222in;height:0.434722in;">
</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><I>Rilzabrutinib granted orphan drug designation in the US for sickle cell disease </I></FONT></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Fourth orphan drug designation for rilzabrutinib in rare diseases </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Under regulatory review in the US, the EU, and China in immune thrombocytopenia </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify"><B>Paris, June</B><B></B><B>&nbsp;3, 2025</B>. The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, a novel,
advanced, oral, reversible Bruton&#146;s tyrosine kinase (BTK) inhibitor that works via multi-immune modulation, to target a reduction in vaso-occlusive crises, which may occur via inflammation, in sickle cell disease. The FDA grants orphan drug
designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#7900e6"><B><I>Karin Knobe, MD, PhD </I></B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Global Head of Development, Rare Diseases </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:6%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;Receiving our fourth orphan drug designation for rilzabrutinib reinforces our continued dedication to
developing medicines to address the unmet medical needs of people living with rare diseases. People with sickle cell disease often live with severe episodes of pain from vaso-occlusive crises and other complications that can significantly impact
both quality of life and life expectancy. There remains a need for novel treatment approaches to address these experiences by modulating the immune system responses that can contribute to sickle cell disease pathogenesis.&#148; </I></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to sickle cell disease, rilzabrutinib has received orphan drug designation for immune thrombocytopenia (ITP) in the US, the EU, and Japan, for <FONT
STYLE="font-family:arial; font-size:10pt" COLOR="#7900e6"><U>warm autoimmune hemolytic anemia</U></FONT><FONT STYLE="font-family:arial"> (wAIHA) in the US and the EU, and for
</FONT><FONT STYLE="font-family:arial; font-size:10pt" COLOR="#7900e6"><U>IgG4-related disease</U></FONT><FONT STYLE="font-family:arial"> <FONT STYLE="white-space:nowrap">(IgG4-RD)</FONT> in the US. </FONT></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The safety and efficacy of rilzabrutinib have not been determined by any regulatory authority. Rilzabrutinib is currently under regulatory review in the US, the EU, and
in China for its potential use in ITP. The target action date for the FDA regulatory decision for ITP, which was granted fast track designation, is August&nbsp;29, 2025. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><I>Sickle cell disease supporting data</I> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Preclinical data on sickle cell disease was <FONT STYLE="font-family:arial; font-size:10pt" COLOR="#7900e6"><U>presented at ASH 2024</U></FONT><FONT
STYLE="font-family:arial"> showing that rilzabrutinib helped reduce vaso-occlusion &#150;blockage of blood vessels &#150; and inflammation in transgenic mice with sickle cell disease. </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><I>About rilzabrutinib</I> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Rilzabrutinib is
a novel, advanced, oral, reversible Bruton&#146;s tyrosine kinase (BTK) inhibitor that has the potential to be an effective new medicine for several rare immune-mediated or inflammatory diseases by working to restore immune balance via multi-immune
modulation. BTK, expressed in B cells, macrophages, and other innate immune cells, plays a critical role in multiple immune-mediated disease processes and inflammatory pathways. With the application of Sanofi&#146;s TAILORED COVALENCY<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> technology, rilzabrutinib can selectively inhibit the BTK target while potentially reducing the risk of <FONT STYLE="white-space:nowrap">off-target</FONT> side effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><I>About sickle cell disease</I> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Sickle cell
disease is a group of rare, genetic blood disorders in which red blood cells are misshapen, typically in a sickle or crescent shape, causing them to get stuck in small blood vessels, blocking blood flow. This can lead to episodes of severe pain as
well as other health complications including infections, stroke, lung, eye, and kidney disease. Sickle cell disease affects more than 100,000 people in the US, approximately 90% of whom are African American and
<FONT STYLE="white-space:nowrap">3-9%</FONT> of whom are Hispanic or Latino. Approximately 1 in 365 babies of African </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g81295g04g02.jpg" ALT="LOGO" STYLE="width:0.602083in;height:0.159028in;">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1/2</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
American descent born in the US have sickle cell disease, while an estimated 1 in 13 are carriers of the disease. People in the US with sickle cell disease have an estimated life expectancy that
is 20 years shorter than average. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><I>About Sanofi</I> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Sanofi&nbsp;is an R&amp;D driven, <FONT STYLE="white-space:nowrap">AI-powered</FONT> biopharma company committed to improving people&#146;s lives and
creating compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more.<I> </I>Our
team is guided by one purpose: we chase the miracles of science to improve people&#146;s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare,
environmental, and societal challenges of our time.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><I>Media Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Sandrine
Guendoul</B> | +33 6 25 09 14 25 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Evan Berland</B> | +1 215 432 0234 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>evan.berland@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>L&eacute;o Le
Bourhis</B> | +33 6 75 06 43 81 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>leo.lebourhis@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Victor Rouault</B> | +33 6 70 93 71 40 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>victor.rouault@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Timothy Gilbert</B> | +1 516 521 2929 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#7900e6"><I>Investor Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thomas Kudsk Larsen</B> |+44 7545 513 693 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Aliz&eacute;
Kaisserian </B>| +33 6 47 04 12 11 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Felix Lauscher </B>| +1 908 612 7239 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Keita Browne </B>| +1 781 249 1766 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Nathalie Pham </B>|
+33 7 85 93 30 17 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Tarik Elgoutni </B>| +1 617 710 3587 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thibaud Ch&acirc;telet</B> | +33 6 80 80 89 90 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Yun Li</B> | +33 6
84 00 90 72 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>yun.li3@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><B>Sanofi
forward-looking statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial">This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future
financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;,
&#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148; and similar expressions. Although Sanofi&#146;s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data
and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as
their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and
commercial success of therapeutic alternatives, Sanofi&#146;s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related
pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact
that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also
include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in
Sanofi&#146;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking
information or statements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:arial">All trademarks mentioned in this press release are the property of the Sanofi group. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g81295g04g02.jpg" ALT="LOGO" STYLE="width:0.602083in;height:0.159028in;">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/2</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d81295dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:14pt"><B>Press Release</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g81295g04g01.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><I>ASCO: new Sarclisa data support subcutaneous administration with
<FONT STYLE="white-space:nowrap">on-body</FONT> injector </I></FONT></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">New data from two clinical studies demonstrated that Sarclisa administered subcutaneously via an investigational <FONT
STYLE="white-space:nowrap">on-body</FONT> injector shortened treatment time to minutes with similar efficacy and safety compared to intravenous infusion </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Studies used Enable Injections&#146; enFuse<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP><SUP
STYLE="font-size:75%; vertical-align:top"> </SUP><FONT STYLE="white-space:nowrap">on-body</FONT> injector, an automated hands-free injector </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Data will form<B> </B>the basis of global regulatory submissions across all currently approved lines of treatment
</P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify"><B>Paris, June</B><B></B><B>&nbsp;3, 2025.</B> New data from two clinical studies of the investigational use of Sarclisa
administered subcutaneously (SC) via an <FONT STYLE="white-space:nowrap">on-body</FONT> injector (OBI) (also referred to as an <FONT STYLE="white-space:nowrap">on-body</FONT> delivery system) in relapsed or refractory multiple myeloma (R/R MM)
support the potential use of this innovative delivery method to advance patient care, while upholding Sarclisa&#146;s efficacy and safety profile. The results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and
include full data from the <FONT STYLE="font-family:arial; font-size:10pt" COLOR="#7900e6"><U>IRAKLIA phase 3 study</U></FONT><FONT STYLE="font-family:arial">, the first to incorporate the use of an OBI in the treatment of MM, and demonstrate <FONT
STYLE="white-space:nowrap">non-inferior</FONT> efficacy and pharmacokinetics compared to Sarclisa intravenous (IV)&nbsp;infusion. </FONT></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#7900e6"><B><I>Alyssa Johnsen, MD, PhD </I></B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:3%; font-size:10pt; font-family:arial">Global Therapeutic Area Head, Immunology and Oncology Development </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;Our subcutaneous clinical program is rooted in our mission to address patient needs and reduce treatment burden in
multiple myeloma. We believe the novel <FONT STYLE="white-space:nowrap">on-body</FONT> injector represents a significant innovation that could improve and streamline the treatment process for both patients and providers. We are pleased to share
these data, the first to evaluate an <FONT STYLE="white-space:nowrap">on-body</FONT> injector with a multiple myeloma treatment, and look forward to potentially bringing this formulation and administration option to the multiple myeloma
community.&#148; </I></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">The OBI offers the potential to improve the overall patient experience in MM treatment. Recent studies and surveys suggest the
use of an OBI may be associated with greater convenience, flexibility, and patient satisfaction compared to IV or manual SC administration methods.<SUP STYLE="font-size:75%; vertical-align:top"> </SUP>In addition, an OBI may also streamline the
administration process for providers, potentially reducing the physical burden on nurses and enabling them to possibly move freely through the use of a hands-free device while monitoring the patient during injection. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">The IRAKLIA phase 3 study and the IZALCO phase 2 study presented at ASCO were conducted using Enable Injections&#146; enFuse<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> hands-free OBI, an automated injector designed to subcutaneously administer high-volume medicines beginning with the click of a button, to administer the hyaluronidase-free SC formulation of
Sarclisa. The enFuse device uses a 30 gauge, hidden, and retractable needle that is smaller compared to some of the commonly used large-volume SC injection needles, which may support patient comfort. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">The safety and efficacy of Sarclisa SC administered with the OBI or manual administration are investigational and have not been approved for use by any
regulatory authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><I>IRAKLIA phase 3 study </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">IRAKLIA is a global, randomized, open-label, pivotal phase 3 <FONT STYLE="white-space:nowrap">non-inferiority</FONT> study comparing Sarclisa SC
administered via an OBI and Sarclisa IV, both in combination with pomalidomide and dexamethasone (Pd) in adult patients with R/R MM who have received at least one prior line of treatment. At the data <FONT STYLE="white-space:nowrap">cut-off</FONT>
of November&nbsp;6, 2024, and a median <FONT STYLE="white-space:nowrap">follow-up</FONT> of 12 months, the study demonstrated: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g81295g04g02.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Primary endpoints </I></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Objective response rate (ORR) with Sarclisa SC-Pd was 71.1% </B>compared to 70.5% with Sarclisa IV-Pd, establishing <FONT
STYLE="white-space:nowrap">non-inferiority</FONT> (risk ratio [RR] 1.008; 95% confidence interval [CI]: <FONT STYLE="white-space:nowrap">0.903-1.126;</FONT> p=0.0006). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Observed Sarclisa mean (standard deviation [SD]) concentration before dosing (C trough) at steady state (C6D1 <FONT
STYLE="white-space:nowrap">pre-dose)</FONT> with Sarclisa SC-Pd was 499 (259) ug/mL</B> compared to 341 (169) ug/mL with Sarclisa IV-Pd, establishing <FONT STYLE="white-space:nowrap">non-inferiority</FONT> (geometric mean ratio [GMR] 1.532; 90% CI: <FONT
STYLE="white-space:nowrap">1.316-1.784).</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify"><I>Secondary endpoints </I></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Very good partial response (VGPR) or better rates</B> <B>were consistent </B>between Sarclisa SC-Pd and Sarclisa
IV-Pd at 46.4% and 45.9%, respectively (RR 1.011; 95% CI: <FONT STYLE="white-space:nowrap">0.841-1.215;</FONT> p&lt;0.0001). </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Observed Sarclisa mean (SD) C trough at 4 weeks (C2D1 <FONT STYLE="white-space:nowrap">pre-dose)</FONT> with Sarclisa
SC-Pd was 421 (215) ug/mL</B> compared to 302 (117) ug/mL with Sarclisa IV-Pd (GMR 1.302; 90% CI <FONT STYLE="white-space:nowrap">1.158-1.465).</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Systemic infusion reactions (IR) were significantly lower with Sarclisa SC-Pd, </B>occurring in only 1.5% of patients
compared to 25% of those treated with Sarclisa IV-Pd (RR: 0.061; 95% CI: <FONT STYLE="white-space:nowrap">0.022-0.164;</FONT> p&lt;0.0001). Of note, nearly all IRs occurring were grade&nbsp;1 or 2 and resolved within one day. No patients in the
Sarclisa SC-Pd arm discontinued treatment due to a systemic IR. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Most Sarclisa SC-Pd-treated patients (70%) reported being satisfied or very satisfied with their injection
</B>compared<B> </B>to 53.4% in the Sarclisa IV-Pd arm, demonstrating the positive impact of this innovative method of administration on the patient experience (OR 2.036; 95% CI: <FONT STYLE="white-space:nowrap">1.425-2.908;</FONT> p=0.0001).
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>99.9% of Sarclisa SC OBI injections were successfully delivered</B> with no significant safety concerns related to
the OBI. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Progression-free survival (PFS) rates at 12 months were also similar,</B> reaching 66.1% for patients treated with
Sarclisa SC-Pd compared to 65.1% of patients treated with Sarclisa IV-Pd (HR 0.985; 95% CI: <FONT STYLE="white-space:nowrap">0.726-1.338).</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">The overall safety profile of Sarclisa SC-Pd observed in this study was consistent with the established safety profile of Sarclisa IV-Pd, but with a
notably lower rate of systemic IRs. No new safety concerns were observed, except for <FONT STYLE="white-space:nowrap">low-grade</FONT> local injection site reactions (ISRs) associated with SC administration that occurred with a low incidence (0.4%,
n=19/5,145 injections). Nearly all ISRs were grade 1, except for one episode of grade 2. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><B><I>Xavier Leleu, MD,
PhD </I></B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:arial" ALIGN="justify">Head of the Department of Hematology and Myeloma Clinic at the H&ocirc;pital La Mileterie and study investigator
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;Results from the IRAKLIA phase 3 study represent a potentially transformational advancement in the administration
of multiple myeloma treatment. These data not only establish <FONT STYLE="white-space:nowrap">non-inferiority</FONT> between Sarclisa administered both subcutaneously and intravenously across several key endpoints but reinforce the positive impact
that this <FONT STYLE="white-space:nowrap">on-body</FONT> injector could have on the patient treatment experience, as demonstrated by patient satisfaction scores.&#148; </I></P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">In addition to the oral presentation at ASCO, the full data were simultaneously published in the
<I><FONT STYLE="font-family:arial" COLOR="#7900e6"><U>Journal of Clinical Oncology</U></FONT></I>. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#7900e6"><I>IZALCO phase
2 study </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">In addition to the IRAKLIA phase 3 study, Sanofi also presented new data from the randomized, sequential, open-label, IZALCO
phase 2 study evaluating the efficacy and safety of Sarclisa SC administered via manual push or an OBI, in combination with carfilzomib and dexamethasone (Kd) in adult patients with R/R MM who have received one to three prior lines of therapy. At a
median <FONT STYLE="white-space:nowrap">follow-up</FONT> of 10.1&nbsp;months, the study demonstrated: </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>ORR was 79.7% in patients treated with Sarclisa SC-Kd </B>(95% CI: <FONT STYLE="white-space:nowrap">68.8-88.2)</FONT>
validating the prespecified efficacy hypothesis. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g81295g04g02.jpg" ALT="LOGO" STYLE="width:0.601389in;height:0.158333in;">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">With a median <FONT STYLE="white-space:nowrap">follow-up</FONT> of 10 months, <B>VGPR or better rate in patients treated
with Sarclisa SC-Kd was 62.2% and complete response (CR) or better rate was 21.6%</B>. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Only two patients treated with Sarclisa SC-Kd, or 2.7% of recipients, experienced a grade 2 or lower IR event with
manual injection and no IR event occurred with OBI administration; approximately 1% of injections<B> </B>were associated with a local ISR. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">After treatment with both methods, <B>most patients (74.5%) preferred the OBI</B> versus 17% who preferred manual
injection and 8.5% with no preference (p=0.0004; binomial test against the null hypothesis of <FONT STYLE="font-family:Times New Roman">&#8804;</FONT>50% rate). </P></TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">The overall safety profile of Sarclisa SC-Kd observed in this study was consistent with the established safety profile of Sarclisa IV-Kd, with no new
safety concerns observed. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><I>Advancing patient and provider-centric innovation in MM </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">While SC administration is currently available for certain MM treatment regimens through a manual injection, administering large-volume medicines
manually can present significant challenges, including a labor-intensive process for nurses, risk of strain and needlestick injuries, and potential need for larger needles that may compromise patient comfort and increase anxiety. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><B><I>Mehul Desai, PharmD, MBA </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:arial">Vice President, Medical Affairs, Enable Injections </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;We believe multiple myeloma patients deserve a more convenient and comfortable treatment experience and recognize the
crucial role providers play in delivering that care. Through our collaboration with Sanofi, we&#146;ve aspired to advance an <FONT STYLE="white-space:nowrap">on-body</FONT> injector that could transform the treatment experience for patients and
providers alike. The results from the IRAKLIA and IZALCO studies represent a significant step toward our ambition and validate the potential of the <FONT STYLE="white-space:nowrap">on-body</FONT> injector to deliver the same high standard of
efficacy established with intravenous Sarclisa.&#148; </I></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">In addition to IRAKLIA and IZALCO, Sanofi is also evaluating Sarclisa SC administration
via an OBI in the front-line treatment setting. The ISASOCUT phase 2 study conducted by the University of Poitiers, is evaluating Sarclisa in combination with bortezomib, lenalidomide and dexamethasone (VRd) in adult patients with newly diagnosed MM
(NDMM) not eligible for autologous stem-cell transplant (ASCT), while the German-speaking Myeloma Multicenter Group <FONT STYLE="white-space:nowrap">(GMMG)-HD8</FONT> phase 3 study, conducted in collaboration with the GMMG and the German Multiple
Myeloma Study Group Consortium (DSMM), is evaluating Sarclisa SC-VRd induction in NDMM patients who are eligible for ASCT. In addition, results from the IZALCO, IRAKLIA and ISASOCUT studies will be presented at the European Hematology Association
Congress later this month. The IRAKLIA abstract was also hand-selected to be included in the 2025 Best of ASCO program, held later in the summer of 2025, following the ASCO Annual Meeting. The data from these studies, collectively, will form the
basis for global regulatory submissions. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Sarclisa administered subcutaneously via the <FONT STYLE="white-space:nowrap">on-body</FONT> injector or
manual administration is investigational and has not been approved for any use by any regulatory authority. The safety and efficacy of this formulation and delivery method have not been established. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><I>About the IRAKLIA and IZALCO studies </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">IRAKLIA is a randomized, open-label, pivotal phase 3 study evaluating the <FONT STYLE="white-space:nowrap">non-inferiority</FONT> of Sarclisa SC
formulation administered at a fixed dose SC via an OBI versus weight-based dosed Sarclisa IV in combination with Pd in adult patients with R/R MM who have received at least one prior line of therapy. The
<FONT STYLE="white-space:nowrap">co-primary</FONT> outcomes being assessed are ORR, defined as the proportion of patients with stringent CR, CR, VGPR, and partial response (PR) according to the 2016 IMWG criteria assessed by Independent Review
Committee (IRC), and observed C trough at steady state <FONT STYLE="white-space:nowrap">(pre-dose</FONT> at C6D1), defined as observed Sarclisa plasma concentrations. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">IZALCO is a <FONT STYLE="white-space:nowrap">two-part,</FONT> randomized, sequential, open-label, phase 2 study evaluating the efficacy and safety of
Sarclisa SC formulation administered SC via manual push or an OBI in adult patients with R/R MM who have received one to three prior lines of therapy. The primary objective is ORR, as assessed by IRC. The secondary objective is patient preference
for the OBI versus manual administration of Sarclisa SC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g81295g04g02.jpg" ALT="LOGO" STYLE="width:0.601389in;height:0.158333in;">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><I>About Enable Injections </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Based in the US (Cincinnati, OH), Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience
through the development and manufacturing of enFuse. enFuse is an innovative wearable drug delivery platform that is designed to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of
improving convenience, supporting superior outcomes, and advancing healthcare system economics. For more information, visit <FONT STYLE="font-family:arial; font-size:10pt" COLOR="#7900e6"><U>https://enableinjections.com.</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><I>About Sarclisa </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Sarclisa (isatuximab) is approved in more than 50 countries, including in the US, EU, Japan, and China, across multiple treatment lines for MM. Based on
the <FONT STYLE="white-space:nowrap">ICARIA-MM</FONT> phase 3 study, Sarclisa is approved in the US, EU and Japan in combination with Pd for the treatment of patients with R/R MM who have received
<FONT STYLE="font-family:Times New Roman">&#8805;</FONT>two prior therapies, including lenalidomide and a proteasome inhibitor and have relapsed on the last therapy; this combination is also approved in China for patients who have received at least
one prior line of therapy, including lenalidomide and a proteasome inhibitor. Based on the IKEMA phase 3 study, Sarclisa is also approved in more than 50 countries in combination with carfilzomib and dexamethasone, including in the US for the
treatment of patients with R/R MM who have received one to three prior lines of therapy and in the EU for patients with MM who have received at least one prior therapy. In the US, EU, UK, and China, Sarclisa is approved in combination with VRd as a
front-line treatment option in transplant-ineligible NDMM patients, based on the IMROZ phase 3 study. In Japan, Sarclisa is approved in combination with VRd as a front-line treatment option regardless of transplant eligibility. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those
living with cancer. We are committed to transforming cancer care by developing innovative, first and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> immunological and targeted therapies for rare and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> cancers with high unmet need. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For more information on Sarclisa
clinical studies, please visit <FONT STYLE="font-family:arial; font-size:10pt" COLOR="#7900e6"><U>www.clinicaltrials.gov</U></FONT><FONT STYLE="font-family:arial">. </FONT></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #bfbfbf">&nbsp;</DIV>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><I>About Sanofi </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">Sanofi&nbsp;is an R&amp;D driven, <FONT STYLE="white-space:nowrap">AI-powered</FONT> biopharma company committed to improving people&#146;s lives and
creating compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is
guided by one purpose: we chase the miracles of science to improve people&#146;s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare,
environmental, and societal challenges of our time.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7900e6"><I>Media Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Sandrine
Guendoul</B><B></B>&nbsp;|&nbsp;+33 6 25 09 14 25 |&nbsp;<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Evan Berland</B> | +1 215 432 0234 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>evan.berland@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>L&eacute;o Le
Bourhis</B> | +33 6 75 06 43 81 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>leo.lebourhis@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Victor Rouault</B><B></B>&nbsp;|&nbsp;+33 6 70 93 71 40 |&nbsp;<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>victor.rouault@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Timothy Gilbert</B><B></B>&nbsp;|&nbsp;+1 516 521 2929 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#7900e6"><I>Investor Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thomas Kudsk Larsen</B> |+44 7545 513 693 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Aliz&eacute;
Kaisserian</B><B></B>&nbsp;|&nbsp;+33 6 47 04 12 11 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Felix Lauscher</B><B></B>&nbsp;|&nbsp;+1&nbsp;908&nbsp;612 7239 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Keita
Browne</B><B></B>&nbsp;|&nbsp;+1 781 249 1766 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Nathalie Pham</B><B></B>&nbsp;|&nbsp;+33 7 85 93 30 17 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Tarik Elgoutni </B>| +1 617 710 3587 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Thibaud
Ch&acirc;telet</B> | +33 6 80 80 89 90 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial"><B>Yun Li </B>| +33 6 84 00 90 72 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>yun.li@sanofi.com</U></FONT><FONT STYLE="font-family:arial">
</FONT></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #bfbfbf">&nbsp;</DIV>
<P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g81295g04g02.jpg" ALT="LOGO" STYLE="width:0.601389in;height:0.158333in;">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial"><B>Sanofi forward-looking statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="justify"><I>This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking
statements are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148;, and similar expressions. Although Sanofi&#146;s management believes
that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include
among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties
inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks
associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors,
and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings
with the SEC and the AMF made by Sanofi, including those listed under &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in Sanofi&#146;s annual report on Form
<FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. </I></P>
<P STYLE="margin-top:7pt; margin-bottom:0pt; font-size:7pt; font-family:arial" ALIGN="justify"><I>All trademarks mentioned in this press release are the property of the Sanofi group with the exception of enFuse. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g81295g04g02.jpg" ALT="LOGO" STYLE="width:0.601389in;height:0.158333in;">
 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>d81295dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><B>Exhibit 99.3 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:14pt"><B>Press Release</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g81295g04g01.jpg" ALT="LOGO" STYLE="width:1.52222in;height:0.434722in;">
</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#7900e6"><I>Sanofi Launches 2025 Global Employee Stock Purchase Plan </I></FONT></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify"><B>Paris, June</B><B></B><B>&nbsp;5, 2025.</B> Sanofi&#146;s global employee shareholder plan, Action 2025, opens on June&nbsp;10, 2025, to around
70,000 employees in 55&nbsp;countries. Now in its 11<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company&#146;s growth
and results. In 2024 alone, more than 32,000 Sanofi employees - 40% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.55%<SUP
STYLE="font-size:75%; vertical-align:top">1</SUP> of its capital. </P> <P STYLE="margin-top:10pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#7900e6"><B><I>Paul Hudson
</I></B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial" ALIGN="justify">Chief Executive Officer of Sanofi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;The Board of Directors and I are particularly proud to see the growing participation of our employees in our global
employee shareholder plan, a commitment that has endured for more than a decade. This renewed confidence illustrates their active support for our transformation into a leading biopharmaceutical company at a decisive moment in our history.&#148;
</I></P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="justify">From June 10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>, 2025, employees will be offered shares at a subscription price of <FONT
STYLE="font-family:Times New Roman">&#128;</FONT>72.97, which is equal to a 20% discount on the average of the 20 opening prices of Sanofi shares from May&nbsp;7 to June&nbsp;3, 2025. For every five shares subscribed, employees will be offered one
free matching share (up to a maximum of four matching shares per employee). Every eligible employee may purchase up to 1,500 Sanofi shares within the legal limit (maximum payment amount may not exceed 25% of their gross annual salary, minus any
voluntary contributions already made in employee savings schemes, such as Company Savings Plan and/or Group Savings Plan and/or Group Retirement Savings Plan (PERCO) - voluntary contributions to the PERCOL are not concerned by this limit-during 2025<SUP
STYLE="font-size:75%; vertical-align:top">2</SUP>. </P> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><U>Detailed conditions</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify">An eligibility condition of three months employment by the closing date of the offer period will apply. Eligible staff will be able to subscribe for
shares from June&nbsp;10, 2025 (inclusive) to June&nbsp;30, 2025 (inclusive). The issue is expected to be completed and the delivery of the securities carried out by the end of July 2025. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify">The number of shares offered is limited to 1% of Sanofi&#146;s share capital as of January&nbsp;29, 2025, reduced by the impact of the capital increase
reserved to employees carried out in July 2024 (i.e., 10,386,831 shares). The new shares, including the matching shares (the &#147;Shares&#148;), will be subscribed (or delivered) either directly or through the intermediary of employee mutual funds
(&#147;FCPE&#148;), depending on the regulations and/or tax regime applicable in the various countries of residence of those eligible for the capital increase. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify">The Shares will be fully fungible with the existing ordinary shares comprising the share capital of Sanofi and will acquire dividend rights as from
January&nbsp;1, 2025. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify">The voting rights attached to the subscribed Shares will be exercised directly by the employees. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify">Shares and the corresponding FCPE units subscribed, in France, within the framework of the Sanofi Group savings plan (PEG) must be held for a period of
approximately five years, i.e. until May&nbsp;31, 2030, except upon the occurrence of an early release event provided for under Article R. <FONT STYLE="white-space:nowrap">3324-22</FONT> of the French Labour Code. For shares subscribed outside of
France within the framework of the Sanofi International Group Shareholding Plan (IGSP), this period could be shortened to three years, i.e. until May&nbsp;31, 2028, depending on the legal and tax implications that may arise in the subscriber&#146;s
country. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify">Admission of the Shares to trading on the Euronext Paris market (ISIN Code: FR0000120578) on the same line as the existing shares will be
requested as soon as possible after the completion of the capital increase. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify">This press release does not constitute an offer to sell or a solicitation
to buy Sanofi shares. The offer of Sanofi shares reserved for employees will only be made in countries where such an offer has been registered with or notified to the competent local authorities and/or following the approval of a prospectus by the
competent local authorities, or in </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P><DIV STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:24%">&nbsp;</DIV>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP> Shares held by the employees according to article <FONT STYLE="white-space:nowrap">L.225-102</FONT>
of the French Commercial Code </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP> For employees subscribing under the PEG: The allocation of all
or part of the amount of profit-sharing arrangement (participation and or int&eacute;ressement) and the transfer of available assets from the FCPE &#147;PEG Sanofi Mon&eacute;taire&#148; of the PEG must comply only with the limit of 1,500 shares.
</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g81295g04g02.jpg" ALT="LOGO" STYLE="width:0.602083in;height:0.159028in;">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1/2</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify">
consideration of an exemption from the requirement to prepare a prospectus or to register or notify of the offer, where such procedure is required. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify">More generally, the offer will only be made in countries where all required registration and/or notification procedures have been carried out, approvals
obtained, and procedures for consulting or informing employee representatives followed. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify">This press release is not intended for and should not be
copied to or distributed in countries where such a prospectus has not been approved or such exemption is not available or where all necessary registration, notification, consultation and/or information procedures have not been completed or
authorisations obtained. This relates in particular to Japan, Morocco and the Philippines, where to date formalities are still pending with the authorities but could also relate to other countries. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><I>This press release is prepared in accordance with the exemption from publication of a prospectus under Article 1 4&deg;i) and 5&deg;h) of the
Prospectus Regulation (EU) 2017/1129. It constitutes the document required to meet the conditions for exemption from publication of a prospectus as defined by the Prospectus Regulation. </I></P>
<P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #bfbfbf">&nbsp;</DIV>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#7900e6"><I>About Sanofi </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify">Sanofi is an R&amp;D driven, <FONT STYLE="white-space:nowrap">AI-powered</FONT> biopharma company committed to improving people&#146;s lives and creating
compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more.&nbsp;Our team is
guided by one purpose: we chase the miracles of science to improve people&#146;s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare,
environmental, and societal challenges of our time. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify">Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. </P>
<P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#7900e6"><I>Media Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><B>Sandrine Guendoul</B><B></B>&nbsp;|&nbsp;+ 33 6 25 09 14 25
|&nbsp;<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>sandrine.guendoul@sanofi.com</U></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><B>L&eacute;a Ubaldi </B>| + 33 6 30
19 66 46 |&nbsp;<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>lea.ubaldi@sanofi.com</U></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><B>L&eacute;o Le
Bourhis</B><B></B>&nbsp;|&nbsp;+ 33 6 75 06 43 81| <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>leo.lebourhis@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><B>Victor Rouault</B><B></B>&nbsp;|&nbsp;+ 33 6 70 93 71 40
|&nbsp;<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>victor.rouault@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><B>Evan Berland</B> | +1 215 432 0234 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>evan.berland@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><B>Timothy Gilbert</B> | + 1 516 521 2929 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#7900e6"><I>Investor Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><B>Thomas Kudsk Larsen</B> |+ 44 7545 513 693 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><B>Aliz&eacute; Kaisserian</B> | + 33 6 47 04 12 11 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><B>Felix Lauscher</B> | + 1 908 612 7239 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><B>Keita Browne</B> | + 1 781 249 1766 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><B>Nathalie Pham</B> | + 33 7 85 93 30 17 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><B>Tarik Elgoutni</B> | + 1 617 710 3587 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><B>Thibaud Ch&acirc;telet</B> | + 33 6 80 80 89 90 |
<FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:arial"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="justify"><B>Yun Li </B>| + 33 6 84 00 90 72 | <FONT STYLE="font-family:arial; font-size:8pt" COLOR="#7900e6"><U>yun.li3@sanofi.com</U></FONT><FONT
STYLE="font-family:arial"> </FONT></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g81295g04g02.jpg" ALT="LOGO" STYLE="width:0.602083in;height:0.159028in;">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/2</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g81295g04g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g81295g04g01.jpg
M_]C_X0O517AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@ +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-3HP-CHP-B P
M,#HQ.#HP- !R<C,Y,3 P-        Z !  ,    !__\  * "  0    !
MD* #  0    !    *0         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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MFQPKNH>2[TY.WUJ-W\WZ?Y]?T+%TG^._I]I?TSJ;1-,/QWN\'?SU7^>WUO\
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MVRPML).UIGVMV#Z2]?224__9_^T4 E!H;W1O<VAO<" S+C  .$))300$
M  !+' %:  ,;)4<< @   @  ' )0  AR<C,Y,3 P-!P"!0 J36EC<F]S;V9T
M(%=O<F0@+2 Y.5\Q7S(P,C5?,#9?,#-?4%(@4FEL>F$@ #A"24T$)0
M$%"PLNZSW-W[A2]$9,-_7<0X0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$'@      !      X0DE-
M!!H      VL    &               I    D    !L .0 Y %\ ,0!? #(
M,  R #4 7P P #8 7P P #, 7P!0 %( ( !2 &D ; !Z &$ (  M #$    !
M                          $              )     I
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<    I     %)G:'1L
M;VYG    D     9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG    *0    !29VAT;&]N9P   )     #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     (X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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MD9@:8W/I#O,>JP_P7DGU0^M^1]5<K(RL;&KR;,BL53:2-H!WG;L_>A)3Z/\
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M3N>_Z7TUSOU__P 7?UAZ_P#6*SJ73_0..^JMH]1Y:Z6#:[V[7+T]))3G_5[
MNZ;T+I_3\@M-V+CU4V%AENYC6L=M)CVKBO\ &3]1.N_67J^-F=-]'TJL<4O%
MCRP[@^RS]UWMVV+T5))3B?4SH^7T3ZLX73,TM.1CA_J>F9;[K++1#O;^:]<U
M]=O\5E/7,JWJG2KFXN?;[KJK/YFQT?3E@W4VO_/]K_47H"22GP;_ ,:;ZZ^I
ML^RU;?\ 2>M7M_ZK?_T%W?U(_P 5V/T*^OJ?5;&Y?4:]::V?S-1CZ?O ==<W
M\U_^#_\ !%WR22GGOKWT+-Z_]6\CIN 6#(L?6YOJ':T['M>[W0[\U8/^+3ZD
M=:^K.9FW]3-.W(K8RL5/+S(<7.GVM7?I)*8V-+ZW,&A<"!\PO(OJS_BM^L_3
M/K#@9^2<?[/BWMLL+;"3M:9]K=@^DO7TDE/_V0 X0DE-!"$      %4    !
M 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O
M &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@
M    !P (     0$ _^$0!FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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MR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:  P# 0 "$0,1 #\
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MX9ZLRQ;57J3?4^/AI?)J%(<C-VVV<D(C])D-0"3S8?3W[KW5SG\MS_A8C/\
M(KY =4_';Y:?$VDV;D.Y-Z[2ZTVEV3\>\WG-R4='OG>N<HMM[<I<WU?NL5>=
M.!K\SDH$EJJ#-5M72J25HZB_I]U[K='[C[BZQ^/G5F_.[.Y]Z83KOJSK';61
MW=OC>>X:@T^*P6"Q<1EJ*B01I+55E7.Y6&EI*>.:KK:J2.GIXY9Y(XV]U[K0
M2^67_"V3L^7>.X\)\)?B=L#&[!HJZ>CVYV!\C<KN//[KW'0122)'FJCKW8.;
MVMBMI25:A62D?-Y<QK^M]3:4]U[HLW7_ /PM9_F%86H4=C?&SXE;]H/*&E3
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MI]<W14N7PV-WEFZ+'Y7,[AWAD,+60U@P]!%3I!25,4D];#(RP-[KW6LW1?\
M"U'^9/%NILI7= ?#BLVHSG_?J0[3[=HZE(2PXBW&>WZFH%0J?1VIW35R4(]/
MOW7NMI+^2]_PI*^//\TW<L'Q_P"QMGQ_&SY=2T>6R>WNO*G<']XM@]MXG#4T
MV1R4O5^[JJBQ5:^Z<3B*>6LK=OUU.E8M'#+4TDU;#!5M2^Z]T_\ _"KK+9'&
M?R2_DC!054M-%FM]?'O$Y-8G9/N\<>[]CY)J60J06B>LQL+,IX.BQ]^Z]U\[
M;^4+_-V["_E ]H=N=L]8=(]9]P;I[7V!B^NI:CL2OW'C7VS@Z'<=/N6OCP]1
MMRIIIWCSE=04AJHY#I9J.%A8I8^Z]U] /^0I_/G[C_FWU?R[H^U^B>L>K&^.
M6S>N]W8!^O<]NBL.XUW@^_XJ_'Y:+<LU>8?M7V?$8IH64 3L&0V4^_=>ZJH_
ME^?\*V/DO\OOG-\:OC/N3XB?'W:&WOD%W+M'K+/[HV[N3?S[IP^'W#D6Q\&0
MI*BOJ:BAR%=A8I@ZI-!XIRK(!"'U)<RR-&D32,8EK05-!7C0<!7SIQZL68J%
M+'2. \AU_]'3Z^>DNX\1_,W^6=5\E\-NK.9>B^:';U=VY@:BNGPVYL[B4[@S
M57F\=BLK5PR_PU<SMVZ8NJ1'IXZ:6"2$-"$O[KW7T;?ASEO^$K7S)ZGVU@.G
MNI?Y>&$>IQ]/"W5G=G7G6'6??&'KF1*.2@RG^D1:;>VX\W!(1&^1QV4R\%0_
MKBK)@0Y]U[HR7QR_X3>_RVOBU\[MF?/'H7;6[]LU>RL-N"KV9TC6;D_OCT_M
MS?NX:::@I.RMM-N>++[MI:[#X7)UBT-'+DZJAI*J6"JI5IY*:(>_=>ZHT_X6
MR_+3>VW-G?$3X6;6S>0Q.S^R9-[=Y]MX^BJY:6+=46S,AA-L]6X?)I 8S787
M'9JKS60DI9B].]?344^CRTL3K[KW07_\)5OY(OQ0^1WQOWA\[_F)U7MCOB7=
MN_MR=9]*=9;^H%S?7FW]M;(.-I]T;]RVW9V&.W'N7/;JFJ<;315L4U-CZ7&/
M(BO+5W@]U[HV7_"HO^6!_+W^._\ +$SW>O07Q#Z1Z1[8VUW/U)AL3O#J39F-
MZ]J?X3N7)Y#%9O&9.@VO'C<3F:&MHY/T5,$A29$D0JR\^Z]T13_A#U_S/#^8
M#_XBGHO_ -Z_L'W[KW58O_"N3_M\YV;_ .(1Z$_]XP>_=>ZW2OY2G\H7^5[O
MC^6A\&NQ]\_ _P",^_-^]F_%?I3?>_-X]@=8;?WWN7<F[]W["PN=W+G*W,[L
MI<O7QS9+,9":58X7CAIU81PHD:(J^Z]UI,_\*E?@-\>?@/\ S$MJ;>^,6S,;
MUGUGW;\?=H]P3=:X(5$>VMG;M.\M_; S]/M:FJ9ZEL=@<S%LFFR I5?Q4]95
M5"PK'!XHT]U[K=A_D_?*'.]-?\)H>H?E%NJM;/Y/X]?$7Y([KQO\8EGJ8ZO&
M=![J[DH=@[<D((F%!28/9N.Q<,:D:((D12 !;W7NOG/?RU?C%N_^;A_-*Z?Z
M=[BWKN3/5_R([9W;V=\A.Q*JM63=F:VYAZ'</;7;V7&5E1HZ;=&[L?AJRDI*
MDQ21P9&OA<Q.B^,^Z]U]37,_R%_Y/.;ZYJ>L)OY?/QTH,!48:3"#-X;9_P#"
M.QJ:G>D-(M;3=K4-7#V4F9A0ZUK6RK51E =G+7)]U[KY8GSX^/6]?Y/O\U+L
M_J?JG>V=&=^*W=6R^Q>D=^SS"FW'_=ZKHML=O=39+*U6/CH8*C/4&WL[04^3
MD@CAIYZR&?1&D;",>Z]U]![_ (4R]CX[N/\ X3Y[I[=P\#4V([4D^(78^*IF
MD\K4^.WQOK8.YZ&!I=*>1HJ;**I:PO:]A[]U[K6>_P"$@GQ0^,/RO[_^9>W?
MDW\?>G^_L+M7ISKC+[7QO;NP-N;^H]N9*MWOE*2OK<)2[DH<A3XVKKJ:-(YI
M8D61TC"ZM-P?=>Z^ACUE\,OB5\2=E=MM\7_C9TE\?WWSM:J_OE)U#UMM38,N
MZ%P&(S0PD>=EVYC,?)DXL1_%*HTR2EDA:IE*@&1R?=>Z^0W_ "//^WOG\NO_
M ,6LZL_]WL?OW7NO_]*UC^;E_*;_ )47\V[Y"U>T,?\ )[KKH#^9%C:*/;V0
MS>Q,QMK<V>WR-M8?[;&[3[:ZQGS6'@WAN+:^+@CCB>DKL?N2DQ].D$SS4E+#
M!#)$WL][IV_)$7N1/[?[LG(CJK"^-M(+<HQHLFO3_9,:!92/"8D .214]?EC
MF&/:UWM]FN!M)4,)2ATZ2:!O]*3P:FDU%#GK4S^7W_"2'^:3\:\!N7>_5]-U
M=\MMF[=I9LD]'TOG<M0]IS8JF#/45$?6&\\1A*G+9"*)=0H,)D,S6S?IACD;
MCW&_1%T%G\B[^>_\BOY</R$Z[ZK[@[$WMV-\(]X[AQ^R.Q.J]VYFOSJ=14V9
MK:7%P=E]5_QB2IJMI5FRJDBHR&'I6BQV7QXJ8G@6L-+64ONO=78?\+=_C[NN
M7+?!WY6XZADK-B1XKL3H#<^5B#M3X;<\]71]B[#I*B0*8M6Y\2FX7ALU[8J2
MXY'OW7NAC_X21_S:_B[M+XMU_P#+R[X[-VGTUVQL/L7>^^>HJ_L/.XK:>S^S
M=C;ZJ*//9+!8+<^;K:3%_P!_]M;LER,DN+FDBFK,=4P348J##6BF]U[HW/\
MPK6^5'QFW#_*RSG3NW?D#T[N3MC=7=?3^5V[UOMGL/:VY-ZY3%;?RU;DLUED
MV[@LGD,I2X?&T/KEK)XXJ569(_)Y)(T;W7NJH/\ A#U_S/#^8#_XBGHO_P!Z
M_L'W[KW58O\ PKD_[?.=F_\ B$>A/_>,'OW7NOHQ_P FS_MTW_+?_P#%*OCC
M_P"^LVU[]U[K18_X6Q?]O%?C#_XI7M__ -_GW=[]U[K9+_DZ]$UWR@_X2Z;%
M^.6*E@@S7>7Q<^9/5>!J*J<4M+3;AWQV=W[M[;]35U!5Q#2TV9KX'D:QLBGW
M[KW7S\/Y0?R^H_Y77\TCHSOCNW;NXL3MCJG>V^>L>]=NG$U+;JVM@=W;<W-U
M;O:HEP11<A+FNOJ_+G(RT"+]S/)C6IU&MP/?NO=?7!K_ .8]\!,9TW+\@ZOY
MD_&Q>FXL&NX#ON#N#9%9C)*"2E^[CIZ:FH\Q496KSDJ?MIC(J=\D]1^P(#-^
MW[]U[KY'/\U7Y1P?S4_YK/=O=G1^ S=3A^_>T>O>LND,%DZ-J3/YW$;?V[LW
MIGK^HJL:GFFH,EO-\#!7&D.N6FDKO"2S(??NO=;^_P#PI-ZR7I3_ (3N97II
M*N+()U)0_#3K)*^ 2+#6KL/>/7FU5JX5E591%4C%:U# -9N1?W[KW5&'_"(/
M_LIGYT_^(*ZP_P#>_P M[]U[KZ)&^?\ CR=X?^&MN#_W4U?OW7NOC"?R//\
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)NO=>]^Z]U__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g81295g04g02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g81295g04g02.jpg
M_]C_X06 17AI9@  34T *@    @ " $2  ,    !  $   $:  4    !
M;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4
M    G $[  (    )    L(=I  0    !    O    .@ +<;    G$  MQL
M "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-3HP-CHP-B P
M,#HQ.#HT, !R<C,Y,3 P-        Z !  ,    !__\  * "  0    !
M.: #  0    !    #P         & 0,  P    $ !@   1H !0    $   $V
M 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !     $
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MZ43N.7#P7Z;XJ_K)LU71_]G_[0VL4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M  !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$
M8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,
M   #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M  !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M    "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G
M4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M            4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN
M=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E
M8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R
M;W!296-T5&]P;&]N9P      .$))30/M       0 2P    !  $!+     $
M 3A"24T$)@      #@             _@   .$))300-       $    >#A"
M24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M   *  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O
M9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M!@       3A"24T#^       <   _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))300>       $     #A"24T$
M&@     #:P    8               \    Y    &P Y #D 7P Q %\ ,@ P
M #( -0!? #  -@!? #  ,P!? %  4@ @ %( :0!L 'H 80 @ "T ,0    $
M                         0              .0    \
M         0                         0     0       &YU;&P    "
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P    \     4F=H=&QO
M;F<    Y    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90
M !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O
M<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<    /     %)G:'1L;VYG    .0    -U<FQ4
M15A4     0       &YU;&Q415A4     0       $US9V5415A4     0
M    !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0
M  AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI
M8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53
M;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0
M !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M        "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_
M\        #A"24T$$0       0$ .$))3004       $     CA"24T$#
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M 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M^R7>-?\ V[5_Z43N.7#P7Z;XJ_K)LU71_]DX0DE-!"$      %4    ! 0
M  \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@
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M  (1 0,1 ?_=  0 "/_$ :(    & @,!              <(!@4$"0,* @$
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ILL<=H/!D)#42$)$'<Z??NO=5F?Z*-X_\K'7'_H\^B/\ [9?OW7NO_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
